来源：美通社
再鼎医药获得在大中华区独家开发和商业化BLU-945和BLU-701的权利 合作旨在加速和拓展Blueprint Medicines的新一代EGFR抑制剂的全球开发，计划在大中华区开展BLU-945和BLU-701的临床研究 Blueprint Medicines将获得2,500万美元的预付款，及潜在里程碑付款和特许权使用费
马萨诸塞州剑桥市、中国上海和美国旧金山11月10日 /美通社/ 再鼎医药有限公司:78985-78993. doi:10.18632/oncotarget.12587
[2] Zhou J, Song XB, He H, et al. “Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China”. Asian Pac J Cancer Prev. ;17(3):965-71. doi: 10.7314/apjcp..17.3.965. PMID: 27039821.
[3] Wen S, Dai L, Wang L, et al. “Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer”. Oncologist. Nov;24(11):e1070-e1081. doi: 10.1634/theoncologist.-0572. Epub Mar 22. PMID: 30902917; PMCID: PMC6853120.
[4] International Agency for Research on Cancer, Estimated New Incidence in , lung, both sexes, all ages.
国际癌症研究机构，:估计全年齡段男女新发肺癌病例
11月6日发布.
[5] Govindan R, Page N, Morgensztern D, et al. “Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.” J Clin Oncol. Oct 1;24(28):4539-44. doi: 10.1200/JCO..04.4859. PMID: 17008692.
